This study describes what is, to our knowledge, the previously unknown effect of glatiramer acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS).
D espite growing evidence of the involvement of B cells in multiple sclerosis (MS), it is unclear whether current immunomodulatory therapies can affect dysregulated B-cell functions. It has been reported 1-3 that B cells from patients with MS have lost the ability to produce the regulatory cytokine interleukin 10 (IL-10) but produce increased levels of other potentially inflammatory cytokines, such as IL-6 and lymphotoxin α (LT-α). Evidence from the murine model of MS, experimental autoimmune encephalomyelitis (EAE) suggests that B cells from glatiramer acetate-treated mice are protective in EAE, in part because of increased IL-10 production by B cells. 4, 5 In other studies, 5 ,6 B-cell production of growth factors and inflammatory cytokines, including IL-6, were reduced in mice that received glatiramer acetate. Thus, our goal for the present study was to determine whether glatiramer acetate therapy normalizes cytokine production by B cells from patients with MS. Glatiramer acetate is a synthetic peptide composed of amino acids in a ratio similar to the putative MS autoantigen myelin basic protein. Glatiramer acetate therapy influences T-cell behavior by inducing helper T-cell subtype 2 (T H 2), 7,8 CD4 + , 9 and CD8 + T regulatory cells 10,11 through mechanisms involving the binding of glatiramer acetate to HLA antigen molecules. [12] [13] [14] In addition, there is some evidence 7,15,16 that glatiramer acetate directly influences myeloid cells to produce regulatory cytokines and factors while inhibiting factors that promote T H 1 and T H 17 cell development. In contrast to the direct effect of glatiramer acetate on myeloid cells, glatiramer acetate does not influence B-cell activity directly in vitro. 1 We sought to determine whether B cells from patients with MS who received glatiramer acetate are functionally distinct from B cells in treatment-naive patients with MS. We did this by exposing peripheral B cells from both sets of patients to stimulatory conditions that would induce activation of the major pathways of B-cell activation. These stimulatory conditions include engagement of CD40L, B-cell receptor (BCR), and Toll-like receptor 9 in addition to cytokine supplementation. 17 In the present study, we demonstrated that after 5 days in culture, B cells obtained from patients with MS who received glatiramer acetate failed to respond to additional stimuli when incubated with high doses of CD40L. Furthermore, glatiramer acetate treatment restored the ability of B cells to produce IL-10 and reduced their capacity to secrete LT-α. We also observed that glatiramer acetate therapy transiently diminishes IL-6 production by B cells. Proliferation measured by CFSE dilution showed that B cells from the healthy donors, glatiramer acetate patients, and treatment-naive patients proliferated significantly more on exposure to high-dose CD40L than to low-dose CD40L (Figure 1 ). The B cells from the healthy donors and treatment-naive patients proliferated significantly more on exposure to additional stimuli when cultured with high-dose CD40L, except in the case of treatment-naive patients with IL-2/CpG ( Figure 1A and C). Most notably, B cells from patients receiving glatiramer acetate did not display this CD40L dose effect when combined with additional stimuli; instead B cells in this patient group proliferated to a similar extent when exposed to either low-or high-dose CD40L ( Figure 1B ). Further analysis revealed that B-cell proliferation from the healthy donors, treatment-naive patients, and glatiramer acetate patients were not significantly different in any of the culture conditions containing low-dose CD40L (data not shown). When cultured with high-dose CD40L with IL-4, IL-4/BCR, and IL-2/CpG, B cells from glatiramer acetate and treatmentnaive patients proliferated significantly less compared with those of the healthy donors and treatment-naive patients (eFigure 1D in the Supplement). The B cells from glatiramer acetate patients were less responsive to high-dose CD40L plus IL-4 than were the B cells from treatment-naive patients (eFigure 1D in the Supplement). These results suggest a defect in the ability of patients with MS to respond to high-dose CD40L in combination with additional stimuli that are enhanced by glatiramer acetate therapy.
Effect of Glatiramer Acetate Therapy on Cytokine Production by B Cells
Cytokine levels measured from in vitro culture supernatants of the B-cell assays demonstrated differences among the co- Cytokine production by B cells from healthy donors, patients with multiple sclerosis (MS) who were receiving glatiramer acetate, and treatment-naive patients with MS from in vitro culture supernatants (high-dose CD40L). A, IL-10 secretion on day 5; similar results were observed on day 3. B, Lymphotoxin α (LT-α) production on day 3. Bars indicate mean values; and limit lines, SD. The number of data points is provided under each bar.
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horts. For example, CD19 + B cells from treatment-naive patients produced significantly lower levels of IL-10 in all conditions tested compared with the cytokine levels in healthy donors and glatiramer acetate patients (Figure 2A ). In fact, B cells from glatiramer acetate patients secreted IL-10 at levels equivalent to those in healthy donors and up to 6.5-fold greater than levels in treatment-naive patients ( Figure 2A ). Similar results were observed in low-and high-dose CD40L conditions. The B cells from treatment-naive patients produced up to 19.0-fold more LT-α compared with healthy donors and up to 16.2-fold more LT-α compared with glatiramer acetate patients ( Figure 2B ). The LT-α levels were similar in the glatiramer acetate patients and healthy donors, suggesting that glatiramer acetate therapy reduced B-cell secretion of LT-α. The levels of LT-α declined in the cultures by day 5 to less than 150 pg/mL in all glatiramer acetate and treatment-naive cultures. The B cells cultured with CD40L alone did not produce IL-6 (data not shown); however, the combination of high-dose CD40L with additional stimulatory molecules induced robust IL-6 production by B cells from treatment-naive patients ( Figure 3B ) compared with B cells from healthy donors. In contrast, IL-6 production by the patients receiving glatiramer acetate was not significantly different from the production in healthy donors or treatment-naive patients (data not shown). However, we observed that the glatiramer acetate cohort contained a subset of patients that produced high amounts of IL-6. To determine whether the glatiramer acetate patients who produced high amounts of IL-6 were clinically distinct, we mathematically defined IL-6 high (n = 3) glatiramer acetate patients as those with IL-6 levels that were 2 SDs above the mean of healthy donors in the same condition groups and compared them with the IL-6 low (n = 7) glatiramer acetate patients. Age, years since diagnosis, and months since the most recent re- The levels of IL-6 in healthy donors, patients with multiple sclerosis (MS) who were receiving glatiramer acetate, and treatment-naive patients with MS on day 3. A, The length of glatiramer acetate therapy from IL-6 low and IL-6 high patients. B, IL-6 production from treatment-naive patients, patients who received glatiramer acetate for less than 32 months, patients who received glatiramer acetate for more than 32 months, and healthy donors. Bars indicate mean values; and limit lines, SD. The number of data points is provided under each bar. 
IL-6
low groups. Surprisingly, patients whose B cells produced larger amounts of IL-6 had been receiving glatiramer acetate therapy longer than were those whose B cells produced reduced amounts of IL-6 ( Figure 3A) . The IL-6 levels produced by B cells from patients who had been receiving glatiramer acetate therapy for more than 32 months or less than 32 months revealed that, in response to CD40L plus IL-4, there was diminished IL-6 production by B cells from glatiramer acetate patients who had been receiving therapy for less than 32 months compared with treatmentnaive patients and healthy donors ( Figure 3B ). Because only 2 of the 3 patients who had received therapy for more than 32 months had data available in the CD40L plus IL-4 condition, we were not able to establish whether the level of IL-6 produced by B cells from patients receiving glatiramer acetate was significantly different from other patient groups. In the presence of CD40L plus IL-4/BCR or IL-2/CpG, B cells from glatiramer acetate (<32 months) patients had significantly reduced IL-6 production compared with the production in treatment-naive patients and glatiramer acetate patients who had received therapy for more than 32 months. In contrast, B cells from patients receiving glatiramer acetate therapy for more than 32 months produced elevated levels of IL-6 compared with B cells from healthy donors, patients who received glatiramer acetate for less than 32 months, and treatment-naive patients ( Figure 3B ).
The Effect of Glatiramer Acetate on the Phenotypic Composition of B Cells
The B cells can be subdivided into unique subsets, each with a unique role in the immune system, based on the expression of surface molecules. 18 To determine whether glatiramer ac- treatment-naive patients than in glatiramer acetate patients and healthy donors ( Figure 4B ). This finding suggests that B cells from treatment-naive patients were producing a larger quantity of IL-6, in agreement with what is excreted into the supernatants during in vitro stimulation. The majority of IL-6 + B cells in both patient groups were naive B cells (CD27 − ) that expressed CD24 and high levels of CD1d.
The frequency of B10 cells was not significantly different ex vivo (eFigure 2L in the Supplement) and, after 48 hours of stimulation with BCR/CpG, glatiramer acetate patients had fewer IL-10 + B cells than did healthy donors ( Figure 4C ). Despite a diminished frequency of IL-10 + B cells in the glatiramer acetate patients, the intensity of IL-10 production by these IL-10 + B cells from all 3 cohorts was similar ( Figure 4D ). ; however, we found no significant differences in the frequency of these populations within the patient groups (data not shown). 
Immunoglobulin Titers in B Cells From Glatiramer Acetate Patients
Despite the diminished frequency of IL-10 + B cells by intracellular staining at 48 hours in glatiramer acetate patients, we observed high levels of IL-10 in B cell supernatants from 3-and 5-day B-cell stimulation cultures (data not shown and Figure 2A ). Because IL-10 production is the defining feature of B10 and B10 PRO cells and human IL-10-producing B cells are not uniquely confined to any phenotypic population, 20 we reasoned that glatiramer acetate therapy may influence the activation of B cells beyond 48 hours. One report 24 on mice demonstrated that IL-10-producing B cells went on to become IgM-and IgG-secreting plasmablasts and plasma cells and to produce significant levels of serum immunoglobulin. We thus hypothesized that glatiramer acetate therapy influences in vitro differentiation of B cells into antibody-secreting cells, and we tested this by quantifying IgM and IgG levels using in vitro culture supernatants from the B-cell stimulations. Because IL-2/CpG stimulation induces the greatest amount of antibody production, only B-cell stimulation with high-dose CD40L + IL-2/CpG is shown ( Figure 5 ). B cells from glatiramer acetate patients produced significantly more IgM compared with B cells from treatment-naive patients and healthy donors. (Figure 5A ). The levels of IgG produced by B cells obtained from the glatiramer acetate patients were also higher compared with levels from treatment-naive patients and healthy donors ( Figure 5B ). Despite the elevated immunoglobulin production in vitro, serum levels of IgM ( Figure 5C ) and IgG ( Figure 5D ) were similar among the patient groups. The exact contribution of B-cell-derived cytokines in MS is not clear. The overproduction of LT-α by B cells from treatment-naive patients is in agreement with previous observations 2,31 but, although LT-α plays an important role in some EAE models, its role in MS is unknown 32 and the differential temporal regulation suggests more nuanced regulation than previously described. What is clear is that B-cellderived IL-6 promotes EAE, 33 and B cells that re-emerge after B-cell depletion therapy in patients with MS produce less IL-6 than do B cells in treatment-naive patients with MS. develop parasitic infections, which provoke a T H 2 response, experience an increase in the frequency of IL-10-producing B cells that in turn dampen interferon gamma production by neuroantigen-specific T cells. 35 Although we observed that the B cells in patients receiving glatiramer acetate produced more IL-10 after 3 to 5 days of in vitro activation regardless of the length of glatiramer acetate therapy, the frequency of B10 and B10 PRO cells was not significantly different than the frequency in treatment-naive patients at 48 hours after stimulation. The memory B-cell pool harbors most B10 B cells. The frequency of CD27 + memory B cells is decreased in patients with MS who are receiving glatiramer acetate and thus could account for the similar frequency of IL-10-producing B cells in the glatiramer acetate and control cohorts. The B cells producing IL-10 in the glatiramer acetate patients have similar levels of IL-10 detected by flow cytometry in comparison with the control cohorts. The naive B-cell pool may harbor IL-10-producing B cells, but they likely require longer periods of stimulation than what we used in the present study to upregulate Toll-like receptor 9 and respond to CpG. 36 Whether these glatiramer acetate-induced late IL-10-producing B cells can control the balance of inflammatory and regulatory T cells remains unknown. However, 2 patients who experienced exacerbations while receiving glatiramer acetate therapy harbored B cells with a deficit in IL-10 production and high IL-6 production in vitro that were similar to the production in patients with untreated MS.
